NASDAQ:PACB - Pacific Biosciences Stock Price, Price Target & More

Pacific Biosciences trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences (NASDAQ:PACB) released its earnings results on Thursday, February, 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $24.94 million for the quarter, compared to the consensus estimate of $21.89 million. Pacific Biosciences had a negative return on equity of 98.98% and a negative net margin of 98.63%. Pacific Biosciences's quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.21) earnings per share. View Pacific Biosciences' Earnings History.

Pacific Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, April, 24th 2018. View Earnings Estimates for Pacific Biosciences.

3 Wall Street analysts have issued 1 year target prices for Pacific Biosciences' stock. Their predictions range from $4.00 to $8.00. On average, they anticipate Pacific Biosciences' share price to reach $6.2667 in the next twelve months. View Analyst Ratings for Pacific Biosciences.

Pacific Biosciences saw a decline in short interest in March. As of March 29th, there was short interest totalling 10,469,372 shares, a decline of 19.4% from the March 15th total of 12,986,469 shares. Based on an average daily trading volume, of 1,118,752 shares, the short-interest ratio is currently 9.4 days. Currently, 9.0% of the company's stock are short sold.

Some companies that are related to Pacific Biosciences include Rocket Pharmaceuticals (RCKT), Omeros (OMER), Triple-S Management (GTS), Anika Therapeutics (ANIK), New England Nuclear (LNTH), AMAG Pharmaceuticals (AMAG), RadNet (RDNT), Novavax (NVAX), Endocyte (ECYT), Hanger (HNGR), Mesa Laboratories (MLAB), Jounce Therapeutics (JNCE), Tactile Systems Technology (TCMD), Lannett (LCI), Addus HomeCare (ADUS), Reata Pharmaceuticals (RETA), Dicerna Pharmaceuticals (DRNA) and Heska (HSKA).

News articles about PACB stock have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.32 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $2.53.

Pacific Biosciences has a market capitalization of $341.55 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences employs 456 workers across the globe.

Pacific Biosciences' mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]